<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HC3AC5F1B6E14407584DA2F9494460A3B" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>117 HR 7047 IH: Lowering Costs by Improving Biosimilar Uptake Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2022-03-09</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">117th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. R. 7047</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20220309">March 9, 2022</action-date><action-desc><sponsor name-id="S001180">Mr. Schrader</sponsor> introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend title III of the Public Health Service Act with respect to the determination by the Secretary regarding certain biosimilar application elements, and for other purposes.</official-title></form><legis-body id="H9393D4B5C9A94F28A0D150DB07E12395" style="OLC"><section id="HAF5D344D9026429A872FDD39342CB726" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Lowering Costs by Improving Biosimilar Uptake Act</short-title></quote>.</text></section><section section-type="subsequent-section" id="idF1177559C12D46A49A2FF520235A420D"><enum>2.</enum><header>Determination by Secretary regarding certain biosimilar application elements</header><text display-inline="no-display-inline">Section 351(k)(2)(A)(ii) of the Public Health Service Act (262(k)(2)(A)(ii)) is amended to read as follows: </text><quoted-block style="OLC" id="H2F83B618448C4CF6ABA264BE7E6AD961" display-inline="no-display-inline"><clause id="H01648F874F2A4EC08A5C3F7D91C87DD0"><enum>(ii)</enum><header>Determination by secretary regarding certain application elements</header><subclause id="H1C85EBBC5BBE4DF0931BC8601C56A89F"><enum>(I)</enum><header>In general</header><text>The Secretary may determine, in the Secretaryâ€™s discretion, that an element described in clause (i)(I), or in clause (i)(IV) with respect to the strength of a biological product, is unnecessary in an application submitted under this subsection. </text></subclause><subclause id="HECD6AB3E3BBA4A45859FA6A0BB5FBDB0"><enum>(II)</enum><header>Use of determination</header><text display-inline="yes-display-inline">If the Secretary makes a determination under this clause that information demonstrating that the strength of the biological product is the same as that of the reference product as described in clause (i)(IV) is unnecessary, the term <term>reference product</term> shall, for purposes of this section with respect to such biological product, include all applicable strengths of the reference product. </text></subclause></clause><after-quoted-block>.</after-quoted-block></quoted-block></section></legis-body></bill> 

